fda compounding semaglutide warning november 2025 Congress Introduces SAFE Drugs Act of 2025, Expanding Oversight of Compounded GLP-1 Drugs and Telehealth Providers Compounded weight loss injections —

Published clinical studies have evaluated investigational retatrutide under controlled research conditions, but those findings should not be interpreted as evidence that this research product is approved for patient care

Before we dive in, let's clear something up: there's no official FDA definition for "GLP-1 friendly." It's not a regulated label

Some studies report average total body weight reductions of 15 to 20 percent or more, rivaling the outcomes of certain bariatric procedures in select individuals

Key Features: Triple receptor agonist: GLP-1, GIP, and glucagon

Reduced Cardiovascular Risk Hashimotos is associated with higher cholesterol and increased cardiovascular risk

The patch does not contain any actual GLP-1 receptor agonist compounds